Global Alosetron Market Research Report 2021

Alosetron (original brand name: Lotronex; originator: GSK) is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.

The global Alosetron market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Alosetron volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Alosetron market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Alosetron Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
0.5 mg Tablets
1 mg Tablets

Segment by Application
Hospital
Drugstore

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Sebela Pharmaceuticals
Amneal
Par Pharmaceutical
West-Ward Pharmaceuticals